Longitudinally extensive transverse myelitis with anti-myelin oligodendrocyte glycoprotein antibodies following SARS-CoV-2 infection
Copyright © 2021 Elsevier B.V. All rights reserved..
We report the case of a patient with symptoms of myelopathy following acute SARS-CoV-2 infection. MRI documented a longitudinally extensive transverse myelitis and further investigation was unremarkable with the exception of positivity for MOG-IgG in serum. This report extends the spectrum of post-COVID-19 neurological syndromes, and documents a very significant improvement to long-term oral corticosteroid therapy in this setting. Further prospective studies are needed to establish the risk of recurrence in this subset of patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:361 |
|---|---|
| Enthalten in: |
Journal of neuroimmunology - 361(2021) vom: 15. Dez., Seite 577739 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dias da Costa, Mariana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoantibodies |
|---|
| Anmerkungen: |
Date Completed 03.12.2021 Date Revised 17.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jneuroim.2021.577739 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331690802 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331690802 | ||
| 003 | DE-627 | ||
| 005 | 20231225214021.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jneuroim.2021.577739 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1105.xml |
| 035 | |a (DE-627)NLM331690802 | ||
| 035 | |a (NLM)34628134 | ||
| 035 | |a (PII)S0165-5728(21)00266-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dias da Costa, Mariana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Longitudinally extensive transverse myelitis with anti-myelin oligodendrocyte glycoprotein antibodies following SARS-CoV-2 infection |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.12.2021 | ||
| 500 | |a Date Revised 17.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
| 520 | |a We report the case of a patient with symptoms of myelopathy following acute SARS-CoV-2 infection. MRI documented a longitudinally extensive transverse myelitis and further investigation was unremarkable with the exception of positivity for MOG-IgG in serum. This report extends the spectrum of post-COVID-19 neurological syndromes, and documents a very significant improvement to long-term oral corticosteroid therapy in this setting. Further prospective studies are needed to establish the risk of recurrence in this subset of patients | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a MOG-IgG | |
| 650 | 4 | |a Myelitis | |
| 650 | 4 | |a Post-infectious myelitis | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Autoantigens |2 NLM | |
| 650 | 7 | |a MOG protein, human |2 NLM | |
| 650 | 7 | |a Myelin-Oligodendrocyte Glycoprotein |2 NLM | |
| 700 | 1 | |a Leal Rato, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Cruz, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Valadas, Anabela |e verfasserin |4 aut | |
| 700 | 1 | |a Antunes, Ana Patrícia |e verfasserin |4 aut | |
| 700 | 1 | |a Albuquerque, Luísa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuroimmunology |d 1985 |g 361(2021) vom: 15. Dez., Seite 577739 |w (DE-627)NLM012614181 |x 1872-8421 |7 nnns |
| 773 | 1 | 8 | |g volume:361 |g year:2021 |g day:15 |g month:12 |g pages:577739 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jneuroim.2021.577739 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 361 |j 2021 |b 15 |c 12 |h 577739 | ||